| Market Cap | 2.59M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -2.45B | Forward P/E | 0.01 | EPS next Y | - | 50D Avg Chg | -60.00% |
| Sales | 2.01B | PEG | - | EPS past 5Y | -20.65% | 200D Avg Chg | -85.00% |
| Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | -18.30% | 52W High Chg | -99.00% |
| Recommedations | 3.50 | Quick Ratio | 1.06 | Shares Outstanding | 235.22M | 52W Low Chg | 10.00% |
| Insider Own | 0.65% | ROA | 4.43% | Shares Float | 233.69M | Beta | 0.80 |
| Inst Own | 0.21% | ROE | - | Shares Shorted/Prior | 19.91M/41.45M | Price | 0.01 |
| Gross Margin | 53.18% | Profit Margin | -121.79% | Avg. Volume | 329,851 | Target Price | - |
| Oper. Margin | 16.14% | Earnings Date | May 6 | Volume | 13,937 | Change | -26.67% |
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren's contracture and Peyronie's disease; SUPPRELIN LA to treat central precocious puberty in children; AVEED to treat hypogonadism; NASCOBAL nasal spray to treat vitamin B12 deficiency; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET for pain management; TESTOPEL, an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX to treat erectile dysfunction, as well as opioid products to treat pain associated with post-herpetic neuralgia. It also provides ADRENALIN, a non-selective adrenergic agonist to treat anaphylaxis; VASOSTRICT, a vasopressin IV solution; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products. In addition, the company offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. Further, it provides specialty pharmaceutical products and over-the-counter products. The company sells its products to specialty physicians, wholesale distributors, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
